Pharmacokinetics of Single-Dose Oral Stavudine in Subjects with Renal Impairment and in Subjects Requiring Hemodialysis

Author:

Grasela Dennis M.1,Stoltz Randall R.2,Barry Michael3,Bone Michael4,Mangold Bernhard5,O'Grady Padraig5,Raymond Ralph1,Haworth Stephen J.1

Affiliation:

1. Bristol-Myers Squibb, Princeton, New Jersey1;

2. GFI Pharmaceutical Services, Inc., Evansville, Indiana2;

3. University of Liverpool3 and

4. Royal Liverpool University Hospital Trust,4 Liverpool, United Kingdom; and

5. Bristol-Myers Squibb, Waterloo, Belgium5

Abstract

ABSTRACT Two open-label studies assessed the pharmacokinetics of single orally administered doses of 40 mg of stavudine in subjects with renal impairment. In one study (study I), 15 subjects with selected degrees of renal impairment, but not requiring hemodialysis, were stratified into three groups of five subjects each according to creatinine clearance (CL CR ) normalized by body surface area (ml/min/1.73 m 2 ): mild (CL CR , 60 to 80), moderate (30 to 50), and severe (≤20) renal impairment. Five healthy subjects (CL CR ≥ 90) were also enrolled. The stavudine area under the curve from 0 h to infinity (AUC 0–∞ ) increased nonlinearly with declining renal function: 1,864, 2,215, 3,609, and 5,928 ng · h/ml for normal renal function and for mild, moderate, and severe renal impairment, respectively ( P = 0.0001 between renal impairment groups). The following stavudine dosage recommendations for renal impairment were proposed for subjects weighing ≥60 kg: CL CR of >50 ml/min/1.73 m 2 , 40 mg every 12 h; CL CR of 21 to 50 ml/min/1.73 m 2 , 20 mg every 12 h; and CL CR of 10 to 20 ml/min/1.73 m 2 , 20 mg every 24 h. For subjects weighing <60 kg, the proposed doses were 30, 15, and 15 mg, respectively, with the same dosing intervals specified above. In a second study (study II), 12 subjects with end-stage renal disease requiring hemodialysis three times a week were enrolled in a randomized, open-label crossover study (dialysis 2 h after dosing and lasting 4 h or dosing without dialysis). There were no statistically significant differences for AUC 0–∞ , AUC 2–6 , time to maximum concentration of drug in serum, half-life, or apparent oral clearance when the two treatment dosage regimens were compared. As a result of study II, the recommended dosing rate for subjects requiring hemodialysis was the same as that proposed for those with severe renal impairment not requiring hemodialysis; however, dosing was recommended to follow hemodialysis and to occur at the same time each day.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3